Anrotinib hydrochloride capsule has therapeutic effect on some non-small cell lung cancer and can control the disease progression. This drug is a kind of targeted inhibitor of tyrosine kinase receptor, which can be used for the treatment of recurrent or metastatic non-small cell lung cancer, advanced non-small cell lung cancer, etc., which still recurs after 2 kinds of systemic chemotherapy treatments. Before the treatment of using this drug, it is necessary to carry out the genetic test on the mutation of epidermal growth factor receptor gene, etc., to make clear whether there is the target of the use of the drug. The use of this drug should be carried out by clinicians experienced in the use of the drug, and regular monitoring of electrocardiogram, electrolytes, coagulation function, liver and kidney function, etc. should be performed after the use of the drug. In the event of hemoptysis, stroke, uncontrollable elevation of blood pressure, severe cardiac insufficiency, transaminases or bilirubin continue to rise and other serious adverse reactions during the use of the drug, need to stop the drug. It is contraindicated in cases of hypersensitivity, centralized squamous lung cancer, risk of hemoptysis, severe hepatic or renal impairment, pregnancy and lactation. The drug needs to be administered after evaluation by a physician and self-administration is absolutely prohibited.